CD33 and acute myeloid leukemia: In the current study, we describe the isolation and characterization of a diverse array of llama SdAbs against the myeloid marker CD33 (Siglec-3)13 and the development of SdAb-based CAR-T cells as a potential treatment for acute myeloid leukemia (AML).